Benzgalantamine (Zunveyl) for Alzheimer's Disease
The FDA has approved Zunveyl (Alpha Cognition), a delayed-release formulation of the prodrug benzgalantamine, for treatment of mild to moderate dementia of Alzheimer's disease (AD). Immediate- and extended-release formulations of the acetylcholinesterase inhibitor galantamine have been available in the US for years for treatment of AD.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-04-03
- DOI
- https://doi.org/10.58347/tml.2025.1726b
- Citations
- 2
- Primary Topic
- Cholinesterase and Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.79